Akero Historical Financial Ratios
| AKRO Stock | USD 43.58 0.29 0.67% |
Akero Therapeutics is presently reporting on over 111 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 2.61 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Akero Therapeutics financial condition quickly.
Akero |
About Akero Financial Ratios Analysis
Akero TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Akero Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Akero financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Akero Therapeutics history.
Akero Therapeutics Financial Ratios Chart
Add Fundamental
Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Income Quality
An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.Most ratios from Akero Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Akero Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.At this time, Akero Therapeutics' Shareholders Equity Per Share is very stable compared to the past year. As of the 28th of March 2025, Price Book Value Ratio is likely to grow to 2.61, while Free Cash Flow Yield is likely to drop (0.13).
| 2022 | 2023 | 2024 | 2025 (projected) | Current Ratio | 18.61 | 29.27 | 19.38 | 14.62 | Net Debt To EBITDA | 2.15 | 1.4 | 1.19 | 2.1 |
Akero Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Akero Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Akero Therapeutics fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Ptb Ratio | 3.14 | 4.36 | 6.54 | 2.29 | 2.49 | 2.61 | |
| Book Value Per Share | 8.22 | 4.86 | 8.38 | 10.18 | 11.17 | 11.73 | |
| Free Cash Flow Yield | (0.0248) | (0.11) | (0.0874) | (0.0433) | (0.12) | (0.13) | |
| Operating Cash Flow Per Share | (2.25) | (2.29) | (2.37) | (2.77) | (3.43) | (3.6) | |
| Pb Ratio | 3.14 | 4.36 | 6.54 | 2.29 | 2.49 | 2.61 | |
| Free Cash Flow Per Share | (2.26) | (2.29) | (2.37) | (2.77) | (3.43) | (3.6) | |
| Roic | (0.35) | (0.31) | (0.59) | (0.33) | (0.36) | (0.38) | |
| Net Income Per Share | (2.9) | (2.52) | (2.89) | (2.79) | (3.75) | (3.94) | |
| Cash Per Share | 8.53 | 5.41 | 9.02 | 10.46 | 11.07 | 6.19 | |
| Pocfratio | (11.46) | (9.24) | (23.09) | (8.44) | (8.12) | (8.52) | |
| Pfcf Ratio | (11.44) | (9.24) | (23.09) | (8.44) | (8.12) | (8.52) | |
| Income Quality | 0.81 | 0.89 | 0.79 | 0.83 | 0.91 | 0.62 | |
| Roe | (0.34) | (0.31) | (0.6) | (0.33) | (0.28) | (0.32) | |
| Ev To Operating Cash Flow | (8.85) | (7.37) | (20.51) | (7.01) | (6.64) | (6.97) | |
| Pe Ratio | (10.25) | (7.31) | (19.62) | (8.09) | (7.41) | (7.78) | |
| Return On Tangible Assets | (1.06) | (0.32) | (0.29) | (0.52) | (0.31) | (0.26) | |
| Ev To Free Cash Flow | (8.83) | (7.37) | (20.51) | (7.01) | (6.64) | (6.97) | |
| Earnings Yield | (0.21) | (0.13) | (0.0976) | (0.14) | (0.051) | (0.12) | |
| Net Debt To E B I T D A | 2.35 | 1.48 | 2.15 | 1.4 | 1.19 | 2.1 | |
| Current Ratio | 20.7 | 7.7 | 18.61 | 29.27 | 19.38 | 14.62 | |
| Tangible Book Value Per Share | 8.22 | 4.86 | 8.38 | 10.18 | 11.17 | 11.73 | |
| Shareholders Equity Per Share | 8.22 | 4.86 | 8.38 | 10.18 | 11.17 | 11.73 | |
| Graham Net Net | 8.07 | 4.65 | 8.25 | 9.61 | 9.94 | 5.11 | |
| Enterprise Value Over E B I T D A | (7.93) | (5.85) | (17.09) | (6.86) | (5.35) | (5.62) | |
| Price Earnings Ratio | (10.25) | (7.31) | (19.62) | (8.09) | (7.41) | (7.78) | |
| Price Book Value Ratio | 3.14 | 4.36 | 6.54 | 2.29 | 2.49 | 2.61 | |
| Price Earnings To Growth Ratio | 0.78 | (0.5) | 5.67 | (2.26) | (0.25) | (0.24) | |
| Price To Operating Cash Flows Ratio | (11.46) | (9.24) | (23.09) | (8.44) | (8.12) | (8.52) | |
| Price To Free Cash Flows Ratio | (11.44) | (9.24) | (23.09) | (8.44) | (8.12) | (8.52) | |
| Ebt Per Ebit | 0.96 | 0.99 | 1.0 | 0.97 | 0.88 | 0.84 | |
| Effective Tax Rate | (5.49E-4) | 2.15E-4 | 4.07E-4 | 0.0279 | 0.0321 | 0.0305 | |
| Company Equity Multiplier | 1.07 | 1.06 | 1.16 | 1.09 | 1.08 | 1.1 |
Pair Trading with Akero Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Akero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Akero Stock
Moving against Akero Stock
| 0.67 | CDIO | Cardio Diagnostics | PairCorr |
| 0.59 | ASMB | Assembly Biosciences | PairCorr |
| 0.56 | SCLX | Scilex Holding | PairCorr |
| 0.56 | CRNX | Crinetics Pharmaceuticals | PairCorr |
| 0.5 | ELVN | Enliven Therapeutics | PairCorr |
The ability to find closely correlated positions to Akero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Akero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Akero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Akero Therapeutics to buy it.
The correlation of Akero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Akero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Akero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Akero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.